Protalix BioTherapeutics, Inc. 8-K

What Happened

• Protalix BioTherapeutics, Inc. announced its financial results for the fiscal quarter ended March 31, 2026 and provided a business and clinical program update via a press release dated May 13, 2026. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8‑K (filed May 13, 2026).
• The Form 8‑K notes, in accordance with Form 8‑K rules, that the furnished information (including Exhibit 99.1) is not “filed” for purposes of Section 18 of the Securities Exchange Act and is not automatically incorporated by reference into registration statements.

Key Details

• Filing date: May 13, 2026.
• Reporting period: fiscal quarter ended March 31, 2026.
• Exhibit included: Press Release (Exhibit 99.1) announcing quarterly financial results and business/clinical update.
• Report signed by Dror Bashan, President and Chief Executive Officer.

Why It Matters

• This 8‑K signals that Protalix released its latest quarterly results and progress updates on its business and clinical programs — information investors typically use to assess short‑term performance and pipeline development.
• The full financial figures and operational details are contained in the furnished press release (Exhibit 99.1); investors should review that release for revenue, earnings (or loss), guidance, and clinical milestones. The filing’s “furnished” status limits Section 18 liability compared with items formally “filed.”